BridgeBio Pharma (BBIO) Competitors $40.09 +1.06 (+2.72%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$39.88 -0.22 (-0.54%) As of 06/10/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BBIO vs. ONC, TEVA, ITCI, GMAB, SMMT, RDY, ASND, MRNA, VTRS, and QGENShould you be buying BridgeBio Pharma stock or one of its competitors? The main competitors of BridgeBio Pharma include Beigene (ONC), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry. BridgeBio Pharma vs. Beigene Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Qiagen BridgeBio Pharma (NASDAQ:BBIO) and Beigene (NASDAQ:ONC) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, community ranking, analyst recommendations and profitability. Does the MarketBeat Community believe in BBIO or ONC? BridgeBio Pharma received 168 more outperform votes than Beigene when rated by MarketBeat users. However, 80.00% of users gave Beigene an outperform vote while only 72.00% of users gave BridgeBio Pharma an outperform vote. CompanyUnderperformOutperformBridgeBio PharmaOutperform Votes18072.00% Underperform Votes7028.00% BeigeneOutperform Votes1280.00% Underperform Votes320.00% Is BBIO or ONC more profitable? Beigene has a net margin of -25.94% compared to BridgeBio Pharma's net margin of -241.44%. BridgeBio Pharma's return on equity of 0.00% beat Beigene's return on equity.Company Net Margins Return on Equity Return on Assets BridgeBio Pharma-241.44% N/A -75.69% Beigene -25.94%-25.12%-14.95% Do analysts recommend BBIO or ONC? BridgeBio Pharma currently has a consensus target price of $57.36, indicating a potential upside of 43.09%. Beigene has a consensus target price of $319.00, indicating a potential upside of 21.10%. Given BridgeBio Pharma's higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Beigene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92Beigene 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer BBIO or ONC? In the previous week, BridgeBio Pharma had 2 more articles in the media than Beigene. MarketBeat recorded 13 mentions for BridgeBio Pharma and 11 mentions for Beigene. BridgeBio Pharma's average media sentiment score of 0.76 beat Beigene's score of -0.14 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beigene 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings and valuation, BBIO or ONC? BridgeBio Pharma has higher earnings, but lower revenue than Beigene. Beigene is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridgeBio Pharma$127.42M59.74-$535.76M-$3.53-11.36Beigene$4.18B7.47-$881.71M-$3.72-70.81 Do institutionals & insiders hold more shares of BBIO or ONC? 99.8% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 48.5% of Beigene shares are owned by institutional investors. 18.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 6.6% of Beigene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, BBIO or ONC? BridgeBio Pharma has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, Beigene has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. SummaryBridgeBio Pharma beats Beigene on 13 of the 18 factors compared between the two stocks. Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BBIO vs. The Competition Export to ExcelMetricBridgeBio PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.61B$6.83B$5.57B$8.67BDividend YieldN/A2.50%5.27%4.19%P/E Ratio-14.078.7927.2220.17Price / Sales59.74263.51421.92161.94Price / CashN/A65.8538.2534.64Price / Book-5.206.677.124.72Net Income-$535.76M$143.49M$3.23B$247.80M7 Day Performance5.44%5.15%3.79%2.76%1 Month Performance17.33%15.42%13.35%9.71%1 Year Performance45.89%6.02%32.04%14.51% BridgeBio Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BBIOBridgeBio Pharma4.5474 of 5 stars$40.09+2.7%$57.36+43.1%+44.1%$7.61B$127.42M-14.07400Positive NewsAnalyst ForecastONCBeigene1.3484 of 5 stars$245.93+0.1%$319.00+29.7%N/A$24.41B$4.18B-29.859,000Trending NewsInsider TradeTEVATeva Pharmaceutical Industries3.6899 of 5 stars$17.26+2.8%$24.50+42.0%+4.5%$19.56B$16.62B-11.9036,800ITCIIntra-Cellular Therapies0.9031 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.285 of 5 stars$21.77+3.9%$39.17+79.9%-18.2%$13.96B$3.12B12.511,660Positive NewsGap UpSMMTSummit Therapeutics3.0203 of 5 stars$17.73-2.7%$37.40+110.9%+176.7%$13.17B$700,000.00-63.32110Analyst RevisionGap UpHigh Trading VolumeRDYDr. Reddy's Laboratories1.2409 of 5 stars$14.73+0.0%$17.00+15.4%+9.5%$12.29B$325.54B23.4524,800ASNDAscendis Pharma A/S3.2894 of 5 stars$175.69+7.9%$216.07+23.0%+31.1%$10.71B$368.70M-24.75640Positive NewsAnalyst ForecastAnalyst RevisionMRNAModerna4.4204 of 5 stars$27.05+1.8%$53.58+98.1%-81.4%$10.46B$3.14B-2.913,900Trending NewsVTRSViatris2.1954 of 5 stars$8.69-1.1%$10.50+20.8%-14.0%$10.20B$14.33B-11.7437,000QGENQiagen3.1584 of 5 stars$44.89-0.5%$48.42+7.9%+6.0%$9.98B$2.00B125.006,030 Related Companies and Tools Related Companies Beigene Alternatives Teva Pharmaceutical Industries Alternatives Intra-Cellular Therapies Alternatives Genmab A/S Alternatives Summit Therapeutics Alternatives Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Moderna Alternatives Viatris Alternatives Qiagen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BBIO) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
